查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1703394

头孢呋辛市场－全球产业规模、份额、趋势、机会和预测，按销售管道、等级、最终用途、地区和竞争细分，2020-2030 年

Cefuroxime Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By Grade, By End Use, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球头孢呋辛市场价值为 5.3088 亿美元，预计到 2030 年将达到 8.4401 亿美元，预测期内年复合成长率(CAGR) 为 5.10%。市场正在经历中等但持续的成长，主要受头孢呋辛的广谱抗菌特性以及对呼吸道和泌尿道感染有效治疗的需求不断增长的推动。

市场概览
预测期 2026-2030
2024年市场规模 5.3088亿美元
2030年市场规模 8.4401亿美元
2025-2030 年复合年增长率 5.10%
成长最快的领域 直接的
最大的市场 亚太

头孢呋辛作为第二代头孢菌素抗生素，因其对革兰氏阳性菌和革兰氏阴性菌均有效而被广泛使用。它常用于治疗支气管炎、鼻窦炎、肺炎、中耳炎和各种皮肤感染等疾病，在全球抗菌治疗中发挥着至关重要的作用。

传染病发病率的上升进一步推动了市场的成长，特别是在医疗基础设施正在快速转型的发展中地区。

关键市场驱动因素

全球医疗保健产业的扩张

主要市场挑战

抗生素抗药性不断上升

主要市场趋势

细菌感染发生率上升

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：COVID-19 对全球头孢呋辛市场的影响

第五章：全球头孢呋辛市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 按销售管道（直接、间接）
    • 按等级（Axetil，钠）
    • 依最终用途（支气管炎、淋病、莱姆病、皮肤感染、耳部感染、咽喉感染等）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第六章：北美头孢呋辛市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第七章：欧洲头孢呋辛市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太头孢呋辛市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第九章：南美头孢呋辛市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第十章：中东与非洲头孢呋辛市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 合併与收购（如有）
  • 产品发布（如有）
  • 最新动态

第 13 章：全球头孢呋辛市场：SWOT 分析

第 14 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 15 章：竞争格局

  • Anhui BBAC Likang Pharmaceutical Co., Ltd.
  • Zhuhai United Laboratories Co.
  • Nectar Lifesciences Ltd.
  • Dhanuka Laboratories Pvt Ltd
  • Aurobindo Pharma Limited
  • Covalent laboratories private limited
  • Orchid Pharma
  • Akums drugs & pharmaceuticals ltd
  • Lupin Limited
  • Hetero Labs Ltd

第 16 章：策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 28276

Global Cefuroxime market was valued at USD 530.88 million in 2024 and is projected to reach USD 844.01 million by 2030, growing at a compound annual growth rate (CAGR) of 5.10% during the forecast period. The market is witnessing moderate yet consistent growth, primarily driven by Cefuroxime's broad-spectrum antibacterial properties and the rising need for effective treatments for respiratory and urinary tract infections.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 530.88 Million
Market Size 2030USD 844.01 Million
CAGR 2025-20305.10%
Fastest Growing SegmentDirect
Largest MarketAsia-Pacific

As a second-generation cephalosporin antibiotic, Cefuroxime is widely prescribed due to its efficacy against both Gram-positive and Gram-negative bacteria. It is commonly utilized in the treatment of conditions such as bronchitis, sinusitis, pneumonia, otitis media, and various skin infections, thereby playing a vital role in global antimicrobial therapy.

Market growth is further fueled by the increasing incidence of infectious diseases, particularly in developing regions where healthcare infrastructure is undergoing rapid transformation.

Key Market Drivers

Expansion of the Global Healthcare Sector

The ongoing growth of the global healthcare industry significantly contributes to the Cefuroxime market's expansion. The hospital segment alone accounted for approximately 40% of the global healthcare market in 2022, with a value exceeding USD 3.9 trillion. This figure is expected to rise to 44% by 2029, reaching a projected market size of USD 5.19 trillion. As hospitals increasingly become central to healthcare delivery, the demand for broad-spectrum antibiotics such as Cefuroxime continues to grow in tandem with healthcare infrastructure improvements, enhanced access to medical services, and evolving treatment protocols.

Cefuroxime is widely utilized in the management of a broad range of bacterial infections, including respiratory tract infections, skin infections, urinary tract infections, and for surgical prophylaxis. As such, it remains an indispensable part of modern antimicrobial therapy.

Key Market Challenges

Rising Antibiotic Resistance

One of the most significant challenges facing the global Cefuroxime market is the increasing prevalence of antibiotic resistance, which is undermining the effectiveness of many broad-spectrum antibiotics, including second-generation cephalosporins. As bacterial strains develop mechanisms to resist antibiotic treatment, the therapeutic reliability of Cefuroxime is being compromised in certain indications.

This trend has led to a more cautious approach to antibiotic prescribing, in alignment with international antimicrobial stewardship efforts, potentially reducing prescription volumes in favor of newer, more targeted therapies. The emergence of multidrug-resistant bacteria presents a growing threat to public health, highlighting the need for innovation in antibiotic development. As an established molecule, Cefuroxime faces limitations in this evolving landscape, presenting both clinical and commercial challenges for pharmaceutical companies striving to balance responsible antibiotic use with sustained product viability.

Key Market Trends

Increasing Incidence of Bacterial Infections

The global rise in bacterial infections represents a key trend shaping the Cefuroxime market's growth trajectory. Bacterial infections are responsible for approximately 7.7 million deaths annually, accounting for one in every eight fatalities and ranking as the second leading cause of death worldwide. Alarmingly, nearly 5 million of these deaths are linked to antibiotic-resistant bacterial strains, highlighting the critical threat posed by antimicrobial resistance.

This escalating public health issue has driven heightened demand for broad-spectrum antibiotics like Cefuroxime, particularly in healthcare settings managing high incidences of respiratory, urinary tract, and skin and soft tissue infections. As a result, Cefuroxime continues to play a vital role in both inpatient and outpatient antimicrobial treatment strategies.

Key Market Players

  • Anhui BBAC Likang Pharmaceutical Co., Ltd.
  • Zhuhai United Laboratories Co.
  • Nectar Lifesciences Ltd.
  • Dhanuka Laboratories Pvt Ltd
  • Aurobindo Pharma Limited
  • Covalent laboratories private limited
  • Orchid Pharma
  • Akums drugs & pharmaceuticals ltd
  • Lupin Limited
  • Hetero Labs Ltd

Report Scope

In this report, the Global Cefuroxime Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cefuroxime Market, By Sales Channel:

  • Direct
  • Indirect

Cefuroxime Market, By Grade:

  • Axetil
  • Sodium

Cefuroxime Market, By End Use:

  • Bronchitis
  • Gonorrhea
  • Lyme Disease
  • Skin Infection
  • Ear Infection
  • Throat Infection
  • Others

Cefuroxime Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cefuroxime Market.

Available Customizations:

Global Cefuroxime Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Cefuroxime Market

5. Global Cefuroxime Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By Grade (Axetil, Sodium)
    • 5.2.3. By End Use (Bronchitis, Gonorrhea, Lyme Disease, Skin Infection, Ear Infection, Throat Infection, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Cefuroxime Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By Grade
    • 6.2.3. By End Use
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cefuroxime Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By Grade
        • 6.3.1.2.3. By End Use
    • 6.3.2. Mexico Cefuroxime Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By Grade
        • 6.3.2.2.3. By End Use
    • 6.3.3. Canada Cefuroxime Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By Grade
        • 6.3.3.2.3. By End Use

7. Europe Cefuroxime Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By Grade
    • 7.2.3. By End Use
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Cefuroxime Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By Grade
        • 7.3.1.2.3. By End Use
    • 7.3.2. Germany Cefuroxime Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By Grade
        • 7.3.2.2.3. By End Use
    • 7.3.3. United Kingdom Cefuroxime Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By Grade
        • 7.3.3.2.3. By End Use
    • 7.3.4. Italy Cefuroxime Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By Grade
        • 7.3.4.2.3. By End Use
    • 7.3.5. Spain Cefuroxime Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By Grade
        • 7.3.5.2.3. By End Use

8. Asia Pacific Cefuroxime Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By Grade
    • 8.2.3. By End Use
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cefuroxime Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By Grade
        • 8.3.1.2.3. By End Use
    • 8.3.2. India Cefuroxime Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By Grade
        • 8.3.2.2.3. By End Use
    • 8.3.3. South Korea Cefuroxime Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By Grade
        • 8.3.3.2.3. By End Use
    • 8.3.4. Japan Cefuroxime Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By Grade
        • 8.3.4.2.3. By End Use
    • 8.3.5. Australia Cefuroxime Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By Grade
        • 8.3.5.2.3. By End Use

9. South America Cefuroxime Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By Grade
    • 9.2.3. By End Use
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Cefuroxime Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By Grade
        • 9.3.1.2.3. By End Use
    • 9.3.2. Argentina Cefuroxime Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By Grade
        • 9.3.2.2.3. By End Use
    • 9.3.3. Colombia Cefuroxime Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By Grade
        • 9.3.3.2.3. By End Use

10. Middle East and Africa Cefuroxime Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By Grade
    • 10.2.3. By End Use
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Cefuroxime Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By Grade
        • 10.3.1.2.3. By End Use
    • 10.3.2. Saudi Arabia Cefuroxime Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By Grade
        • 10.3.2.2.3. By End Use
    • 10.3.3. UAE Cefuroxime Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By Grade
        • 10.3.3.2.3. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cefuroxime Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Anhui BBAC Likang Pharmaceutical Co., Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Zhuhai United Laboratories Co.
  • 15.3. Nectar Lifesciences Ltd.
  • 15.4. Dhanuka Laboratories Pvt Ltd
  • 15.5. Aurobindo Pharma Limited
  • 15.6. Covalent laboratories private limited
  • 15.7. Orchid Pharma
  • 15.8. Akums drugs & pharmaceuticals ltd
  • 15.9. Lupin Limited
  • 15.10. Hetero Labs Ltd

16. Strategic Recommendations

17. About Us & Disclaimer